Skip to main content
Premium Trial:

Request an Annual Quote

Downloads and Upgrades: Certara's Phoenix; TopHat 2.0.0; CLC Bio

Premium

Certara has released a new version of Phoenix, its pharmacokinetic/pharmacodynamic modeling software platform.

Version 1.3 includes updates to several Certara products including Phoenix WinNonlin 6.3; Phoenix NLME 1.2; Phoenix Connect 1.3; AutoPilot Toolkit 2.1 for Phoenix; and IVIVC Toolkit 2.1 for Phoenix WinNonlin

These updates include an improved sampling method for the Quasi-Random Parametric Expectation Maximization algorithm in Phoenix NLME; increased support for developing integrated workflows that include algorithms from third-party software in Phoenix Connect; the ability to execute third-party compute jobs on a high-performance compute cluster through a remote processing server; and other changes.


The Center for Bioinformatics and Computational Biology at the University of Maryland has released TopHat 2.0.0.

The release supports Bowtie 2 and provides improved parallelization and the ability to align RNA sequencing reads across potential fusion points, among other updates.


CLC Bio no longer offers three desktop software packages: CLC DNA Workbench, CLC RNA Workbench, and CLC Protein Workbench.

The features from these three products have been incorporated into the CLC Main Workbench for sequence analysis and gene expression analysis.

The company has also lowered the price of the CLC Main Workbench from $3,950 to $1,999 for industrial customers and from $985 to $399 for academic customers for static single computer licenses. Network licenses now cost $3,999 and $799 for industry and academia, respectively.

The company has also added a limited-term $179 price reduction for the workbench for academic researchers that will last until May 31.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more